A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis"

被引：0

作者：

Ismaila, Afisi S. ^{[1
,2
]}

Haeussler, Katrin ^{[3
]}

Malmenas, Mia ^{[4
]}

Sharma, Raj ^{[5
]}

Compton, Chris ^{[5
]}

Vogelmeier, Claus F. ^{[6
,7
]}

Han, MeiLan K. ^{[8
]}

Halpin, David M. G. ^{[9
]}

机构：

[1] GSK, Value Evidence & Outcomes, 1250 South Collegeville Rd, Collegeville, PA 19426 USA

[2] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada

[3] ICON Plc, ICON Hlth Econ, Munich, Germany

[4] ICON Plc, ICON Hlth Econ, Stockholm, Sweden

[5] GSK, Value Evidence & Outcomes, R&D Global Med, Brentford, England

[6] Philipps Univ Marburg, German Ctr Lung Res DZL, Dept Med Pulm & Crit Care Med, Marburg, Germany

[7] German Ctr Lung Res DZL, Marburg, Germany

[8] Univ Michigan, Div Pulm & Crit Care, Ann Arbor, MI USA

[9] Univ Exeter, Med Sch, Coll Med & Hlth, Exeter, England

来源：

ADVANCES IN THERAPY | 2023年 / 40卷 / 05期

关键词：

COPD; Fixed-effects model; Fluticasone furoate/umeclidinium/vilanterol; Heterogeneity; Indirect treatment comparison; Network meta-analysis; Random effects model; Triple therapy; OBSTRUCTIVE PULMONARY-DISEASE; EFFICACY;

D O I：

10.1007/s12325-023-02495-0

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页码：2556 / 2561

页数：6

共 50 条

[21] ARE PATIENTS WITH COPD MORE ADHERENT TO FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) COMPARED WITH MULTIPLE-INHALER TRIPLE THERAPY IN A REAL-WORLD UK PRIMARY CARE TREATED POPULATION?
Halpin, D. M. G.
Rothnie, K. J.
Banks, V.
Czira, A.
Compton, C.
Wood, R.
Tritton, T.
Massey, O.
Wild, R.
Snowise, N.
Gubba, E.
Sharma, R.
Ismaila, A. S.
Vogelmeier, C. F.
THORAX, 2021, 76 : A20 - A21
[22] Economic benefit of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) by baseline blood eosinophil (EOS) count in COPD in the UK - The IMPACT trial
Ismaila, Afisi S.
Shah, Dhvani
Martin, Alan
Kendall, Robyn
Noorduyn, Stephen G.
Dasari, Priyadarsini
Risebrough, Nancy A.
Compton, Chris
Noorduyn, Stephen G.
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[23] InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use
Singh, D.
Criner, G. J.
Dransfield, M. T.
Halpin, D. M. G.
Han, M. K.
Jones, C. E.
Kilbride, S.
Lange, P.
Lomas, D. A.
Martinez, F. J.
Pascoe, S. J.
Wise, R. A.
Lipson, D. A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[24] Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
Mannino, David
Bogart, Michael
Germain, Guillaume
Huang, Shirley P.
Ismaila, Afisi S.
Laliberte, Francois
Jung, Young
MacKnight, Sean D.
Stiegler, Marjorie A.
Duh, Mei Sheng
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 491 - 504
[25] InforMing the PAthway of COPD Treatment (IMPACT Study)-Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results Based on an Analysis of the North American Region
Wise, R. A.
Criner, G. J.
Dransfield, M. T.
Han, M. K.
Jones, C. E.
Lettis, S.
Martinez, F. J.
Pascoe, S. J.
Quasny, H.
Lipson, D. A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[26] Captain Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, A Pre-Specified Subgroup Analysis
Pavord, I. D.
Fowler, A.
Kerstjens, H.
Papi, A.
Hartley, B.
Goldfrad, C.
Barnes, N.
Oppenheimer, J.
Pizzichini, E.
Lee, L. A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[27] The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: A Pre-Specified Analysis of Safety According to Age
Criner, G. J.
Dransfield, M.
Halpin, D. M. G.
Han, M. K.
Jones, C. E.
Kilbride, S.
Lange, P.
Lomas, D. A.
Martinez, F.
Pascoe, S.
Singh, D.
Wise, R.
Lipson, D. A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[28] InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis o the Western Europe and North America Regions
Bourdin, Arnaud
Criner, Gerard
Devouassoux, Gilles
Dransfield, Mark
Halpin, David M. G.
Han, MeiLan K.
Jones, C. Elaine
Kalhan, Ravi
Lange, Peter
Lettis, Sally
Lipson, David A.
Lomas, David A.
Maria-Tome, Jose M. Echave-Sustaeta
Martin, Neil
Martinez, Fernando J.
Quasny, Holly
Sail, Lynda
Siler, Thomas M.
Singh, Dave
Thomashow, Byron
Watz, Henrik
Wise, Robert
Hanania, Nicola A.
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2021, 8 (01): : 76 - 90
[29] Unveiling the Clinical Profiles for Patients With Asthma and Chronic Obstructive Pulmonary Disease Starting Single-inhaler Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/ UMEC/VI)
Narendra, D.
Baptist, A. P.
Lee, L.
Noorduyn, S. G.
Liu, M.
Igboekwe, E. E.
Veeranki, P.
Kahle-Wrobleski, K.
Paczkowski, R.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[30] Effect Of Fluticasone Furoate (ff)/vilanterol (vi) Compared With Vi On COPD Exacerbations: A Pre-Specified Subgroup Analysis
Dransfield, M. T.
Calverley, P. M.
Bourbeau, J.
Jones, P. W.
Hanania, N. A.
Mahler, D. A.
Vestbo, J.
Wachtel, A.
Martinez, F. J.
Barnhart, F.
Midwinter, D.
Lettis, S.
Crim, C.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187

← 1 2 3 4 5 →